Efficacy of Adding Low Dose Ketamine or Fentanyl to Propofol-dexmedetomidine as Total Intravenous Anesthesia

Ketamine

Brief Summary

Efficacy of adding low dose ketamine or fentanyl to propofol-dexmedetomidine as total intravenous anesthesia for patients undergoing craniotomy in supra tentorial brain tumor

Intervention / Treatment

  • Ketamine (DRUG)
    Total intravenous anesthesia in craniotomy

Condition or Disease

  • Randomised Triple Blinded Study

Phase

  • Phase 1
  • Phase 2

    • Study Design

    Study type: INTERVENTIONAL
    Status: Recruiting
    Study results: No Results Available
    Age: 18 Years to 70 Years
    Enrollment: 40 (ESTIMATED)
    Allocation: Randomized
    Primary Purpose: Other

    Masking

    SINGLE:
    • Investigator

    Clinical Trial Dates

    Start date: Feb 01, 2023 ACTUAL
    Primary Completion: Apr 01, 2024 ESTIMATED
    Completion Date: Apr 01, 2024 ESTIMATED
    Study First Posted: Sep 11, 2023 ACTUAL
    Last Updated: Sep 04, 2023

    Sponsors / Collaborators

    Lead Sponsor: Minia University
    Responsible Party: N/A

    Efficacy of adding low dose ketamine or fentanyl to propofol-dexmedetomidine as total intravenous anesthesia for patients undergoing craniotomy in supra tentorial brain tumor surgery on brain relaxation score, hemodynamics, surgeon satisfaction score , total requirement of intra operative propofol and post operative analgesia

    Participant Groups

    • Ketamine group recieve induction and maintenance doses of ketamine by target controlled infusion

    • Fentanyl group recieve induction and maintenance doses of fentanyl by target controlled infusion

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 70
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    - Patients aged 18-70 years old ASA I - III with GCS 14-15 and BMI\<35 scheduled for elective craniotomy for resection of supratentorial masses

    Exclusion Criteria:

    * Patients will be excluded if they will refuse to give a written consent. Also patients with GCS \< 14 or having endocrine or blood diseases or sever cardiac disease or sever liver disease or renal failure and patients with uncontrolled hypertension or uncontrolled diabetes mellitus and patients have allergy to any of the study drugs.

    This clinical trial is recruiting

    Are you interested in participating in this trial or others? We'd love to help.

    Primary Outcomes

    • 1:perfectly relaxed , 2:satisfactory relaxed , 3:firm brain and 4:bulging brain

    More Details

    NCT Number: NCT06031883
    Other IDs: 685-2023
    Study URL: https://clinicaltrials.gov/study/NCT06031883
    Last updated: Sep 29, 2023